{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:15:52Z","timestamp":1781298952062,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T00:00:00Z","timestamp":1426291200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s13365-015-0316-4","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T11:29:23Z","timestamp":1426246163000},"page":"637-644","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy"],"prefix":"10.1007","volume":"21","author":[{"given":"Tuan","family":"Dong-Si","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gheuens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Gangadharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Made","family":"Wenten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McIninch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoibal","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Richert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Bloomgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,14]]},"reference":[{"key":"316_CR1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jns.2006.06.031","volume":"259","author":"MP Amato","year":"2007","unstructured":"Amato MP, Portaccio E (2007) Clinical outcome measures in multiple sclerosis. J Neurol Sci 259:118\u2013122","journal-title":"J Neurol Sci"},{"key":"316_CR2","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1212\/WNL.0b013e3182768983","volume":"79","author":"C Antoniol","year":"2012","unstructured":"Antoniol C, Jilek S, Schluep M et al (2012) Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology 79:2258\u20132264","journal-title":"Neurology"},{"key":"316_CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1468-1331.2010.03112.x","volume":"18","author":"S Belachew","year":"2011","unstructured":"Belachew S, Phan-Ba R, Bartholom\u00e9 E et al (2011) Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 18:240\u2013245","journal-title":"Eur J Neurol"},{"key":"316_CR4","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C et al (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"316_CR5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","volume":"33","author":"JL Casado","year":"2013","unstructured":"Casado JL, Corral I, Garc\u00eda J et al (2013) Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33:179\u2013187","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"316_CR6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2307\/2683591","volume":"35","author":"WS Cleveland","year":"1981","unstructured":"Cleveland WS (1981) LOWESS: a program for smoothing scatterplots by robust locally weighted regression. Am Stat 35:54","journal-title":"Am Stat"},{"key":"316_CR7","first-page":"1937","volume":"12","author":"A Luca De","year":"1998","unstructured":"De Luca A, Ammassari A, Cingolani A, Giancola ML, Antinori A (1998) Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy. AIDS 12:1937\u20131938","journal-title":"AIDS"},{"key":"316_CR8","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1002\/jcp.24051","volume":"227","author":"S Delbue","year":"2012","unstructured":"Delbue S, Elia F, Carloni C et al (2012) JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol 227:3511\u20133517","journal-title":"J Cell Physiol"},{"key":"316_CR9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP et al (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Translational Neurol 1:755\u2013764","journal-title":"Ann Clin Translational Neurol"},{"issue":"Suppl 1","key":"316_CR10","first-page":"P07.058","volume":"78","author":"T Dong-Si","year":"2012","unstructured":"Dong-Si T, Weber T, Richert N et al (2012) Classification of natalizumab case reports with progressive multifocal leukoencephalopathy [abstract]. Neurology 78(Suppl 1):P07.058","journal-title":"Neurology"},{"key":"316_CR11","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hiv.12008","volume":"14","author":"F Fanjul","year":"2013","unstructured":"Fanjul F, Riveiro-Barciela M, Gonzalez J et al (2013) Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? HIV Med 14:321\u2013325","journal-title":"HIV Med"},{"key":"316_CR12","doi-asserted-by":"crossref","first-page":"e20967","DOI":"10.1371\/journal.pone.0020967","volume":"6","author":"J Gasnault","year":"2011","unstructured":"Gasnault J, Costagliola D, Hendel-Chavez H et al (2011) Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One 6:e20967","journal-title":"PLoS One"},{"key":"316_CR13","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1128\/JVI.02506-10","volume":"85","author":"S Gheuens","year":"2011","unstructured":"Gheuens S, Bord E, Kesari S et al (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85:7256\u20137263","journal-title":"J Virol"},{"key":"316_CR14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-pathol-020712-164018","volume":"8","author":"S Gheuens","year":"2013","unstructured":"Gheuens S, W\u00fcthrich C, Koralnik IJ (2013) Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 8:189\u2013215","journal-title":"Annu Rev Pathol"},{"key":"316_CR15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMc1304828","volume":"370","author":"PS Giacomini","year":"2014","unstructured":"Giacomini PS, Rozenberg A, Metz I et al (2014) Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 370:486\u2013488","journal-title":"N Engl J Med"},{"key":"316_CR16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall CD, Dafni U, Simpson D et al (1998) Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med 338:1345\u20131351","journal-title":"N Engl J Med"},{"issue":"282","key":"316_CR17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53(282):457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"316_CR18","first-page":"191","volume-title":"Evaluation of chemotherapeutic agents","author":"D Karnofsky","year":"1949","unstructured":"Karnofsky D, Burchenal J (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: MacLoad CM (ed) Evaluation of chemotherapeutic agents. Columbia University Press, New York, pp 191\u2013205"},{"key":"316_CR19","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444\u20131452","journal-title":"Neurology"},{"key":"316_CR20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375\u2013381","journal-title":"N Engl J Med"},{"key":"316_CR21","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp.2009.179002","volume":"81","author":"MA Lima","year":"2010","unstructured":"Lima MA, Bernal-Cano F, Clifford DB, Gandhi RT, Koralnik IJ (2010) Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry 81:1288\u20131291","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"316_CR22","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","volume":"73","author":"A Marzocchetti","year":"2009","unstructured":"Marzocchetti A, Tompkins T, Clifford DB et al (2009) Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73:1551\u20131558","journal-title":"Neurology"},{"key":"316_CR23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.22408","volume":"70","author":"FJ Mateen","year":"2011","unstructured":"Mateen FJ, Muralidharan R, Carone M et al (2011) Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol 70:305\u2013322","journal-title":"Ann Neurol"},{"key":"316_CR24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899\u2013910","journal-title":"N Engl J Med"},{"key":"316_CR25","first-page":"1896","volume":"20","author":"MJ Post","year":"1999","unstructured":"Post MJ, Yiannoutsos C, Simpson D et al (1999) Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol 20:1896\u20131906","journal-title":"AJNR Am J Neuroradiol"},{"key":"316_CR26","unstructured":"R Development Core Team (2014) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: www.R-project.org . Accessed December 9, 2014"},{"issue":"Suppl 2","key":"316_CR27","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3949\/ccjm.78.s2.05","volume":"78","author":"RA Rudick","year":"2011","unstructured":"Rudick RA (2011) Multiple sclerosis, natalizumab, and PML: helping patients decide. Cleve Clin J Med 78(Suppl 2):S18\u2013S231","journal-title":"Cleve Clin J Med"},{"key":"316_CR28","unstructured":"Therneau T (2013) A package for survival analysis in S. R package version 2.37-4. Available at: http:\/\/CRAN.R-project.org\/package=survival. Accessed December 9, 2014"},{"key":"316_CR29","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch P, Kappos L, Gold R et al (2011) Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 76:1697\u20131704","journal-title":"Neurology"},{"key":"316_CR30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/1531-8249(199906)45:6<816::AID-ANA21>3.0.CO;2-W","volume":"45","author":"CT Yiannoutsos","year":"1999","unstructured":"Yiannoutsos CT, Major EO, Curfman B et al (1999) Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 45:816\u2013821","journal-title":"Ann Neurol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-015-0316-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-015-0316-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-015-0316-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T15:31:55Z","timestamp":1553700715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-015-0316-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,14]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["316"],"URL":"https:\/\/doi.org\/10.1007\/s13365-015-0316-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725969613.793511829","asserted-by":"object"}]},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,14]]}}}